American Hospital Association Sought 340B Rebate Ban
The trade group submitted formal comments to Congress opposing rebate models within the proposed SECURE 340B Act.
Updated on Sept. 25, 2026 in Healthcare
Live Poll
Should Congress mandate rebate bans to protect hospital cash flow in the 340B drug program?
The American Hospital Association officially expressed its concerns regarding the SECURE 340B Act to Congress. The organization argued that the proposed rebate model would negatively impact hospital cash flow and potentially restrict patient access.
Why it matters
The 340B program is a critical mechanism for healthcare funding, and changes to its operational structure could alter how hospitals manage resources for vulnerable populations. Hospital leaders fear that rigid new reporting and patient definition rules may limit the effectiveness of these essential drug discounts.
The SECURE 340B Act proposes a requirement for drugmakers to provide 340B pricing as an upfront discount for 4 years. The legislation also suggests a 24-month timeframe for qualifying outpatient visits to determine program eligibility.
The players
American Hospital Association
This is a national organization that represents and serves all types of hospitals, healthcare networks, and their patients and communities.
The details
The American Hospital Association explicitly supports contract pharmacy protections within the bill but opposes additional compliance mandates for recordkeeping and audits. The group noted that the current patient definition standards, which have been in place since 1996, remain essential for covering chronically ill patients who might otherwise be excluded under more rigid criteria.
Timeline
The current patient definition standard was implemented in 1996.
The bipartisan SECURE 340B Act was introduced in July 2026.
The American Hospital Association submitted formal comments on September 23, 2026.
Market Landscape
The proposed SECURE 340B Act serves as a direct legislative update to the 340B Drug Pricing Program. This move follows ongoing debates regarding how healthcare entities manage pharmaceutical discounts versus complex rebate systems.
Patients may see changes to how hospitals coordinate prescription drug services if the proposed recordkeeping and patient eligibility rules are adopted. These adjustments could influence the availability of specialized pharmacy services at local community hospitals.
The takeaway
The ongoing debate highlights the tension between administrative oversight and the financial stability of hospital systems. Stakeholders should monitor whether upcoming legislative sessions incorporate the hospital industry's concerns regarding patient definition and operational cash flow.
Further reading
For more on evolving standards in the medical sector, explore the Healthcare section.
Live Poll
Should Congress mandate rebate bans to protect hospital cash flow in the 340B drug program?
